Cargando…

Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer

BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invas...

Descripción completa

Detalles Bibliográficos
Autores principales: Żurek, Michał, Rzepakowska, Anna, Kotuła, Iwona, Demkow, Urszula, Niemczyk, Kazimierz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PeerJ Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029362/
https://www.ncbi.nlm.nih.gov/pubmed/35462765
http://dx.doi.org/10.7717/peerj.13104
_version_ 1784691859223740416
author Żurek, Michał
Rzepakowska, Anna
Kotuła, Iwona
Demkow, Urszula
Niemczyk, Kazimierz
author_facet Żurek, Michał
Rzepakowska, Anna
Kotuła, Iwona
Demkow, Urszula
Niemczyk, Kazimierz
author_sort Żurek, Michał
collection PubMed
description BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invasive pathologies. METHODS: Prospective study included 80 consecutive patients with vocal fold lesions treated at the single otorhinolaryngology centre. All participants had surgical resection of the lesion. Blood samples were collected from each patient before the surgery. Final diagnosis was confirmed on histopathological examination and included 39 (48.75%) non-dysplastic lesions, eight (10%) low-grade dysplasia, six (7.5%) high-grade dysplasia and 27 (33.75%) invasive cancers. The ELISA procedures were performed according to the manufacturer’s instruction. Individual serum concentration of selected proteins was reported in ng/ml: Vascular Endothelial-Cadherin Complex (VE-cad), CD44, Human High mobility group protein B1(HMGB1), Kallikrein 6. RESULTS: The highest mean levels of HMGB1, KLK6 and VE-cad were detected in sera of patients with low-grade dysplasia (81.14, 24.33, 14.17 respectively). Soluble CD44 was the most elevated in patients with non-dysplastic lesions (2.49). The HMGB1, KLK6 and VE-cad serum levels were increasing from non-dysplastic to low-grade dysplasia and followed by the decrease for high-grade dysplasia and invasive cancer, however the differences were not significant (p-values 0.897, 0.354, 0.1 respectively). Patients’ serum had the highest CD44 concentration in non-dysplastic and low-grade dysplasia with the following decrease through high-grade dysplasia and invasive cancer. GERD symptomatic patients had higher levels of KLK6 and CD44 than other patients (p-value 0.06 and 0.084 respectively). There were no significant differences of biomarkers levels related to patients’ gender (p-value from 0.243 to 1) or smoking status (p-value from 0.22 to 0.706). CONCLUSIONS: VE-cad, HMGB1, CD44 and KLK6 did not prove to be reliable biomarkers implicating malignant potential within vocal fold hypertrophic intraepithelial lesions.
format Online
Article
Text
id pubmed-9029362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PeerJ Inc.
record_format MEDLINE/PubMed
spelling pubmed-90293622022-04-23 Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer Żurek, Michał Rzepakowska, Anna Kotuła, Iwona Demkow, Urszula Niemczyk, Kazimierz PeerJ Hematology BACKGROUND: The study was designed to evaluate the potential validity and utility of selected molecular markers in serum samples from patients with specific stages of laryngeal intraepithelial lesions that could serve as diagnostic tools in differentiation of benign and dysplastic lesions from invasive pathologies. METHODS: Prospective study included 80 consecutive patients with vocal fold lesions treated at the single otorhinolaryngology centre. All participants had surgical resection of the lesion. Blood samples were collected from each patient before the surgery. Final diagnosis was confirmed on histopathological examination and included 39 (48.75%) non-dysplastic lesions, eight (10%) low-grade dysplasia, six (7.5%) high-grade dysplasia and 27 (33.75%) invasive cancers. The ELISA procedures were performed according to the manufacturer’s instruction. Individual serum concentration of selected proteins was reported in ng/ml: Vascular Endothelial-Cadherin Complex (VE-cad), CD44, Human High mobility group protein B1(HMGB1), Kallikrein 6. RESULTS: The highest mean levels of HMGB1, KLK6 and VE-cad were detected in sera of patients with low-grade dysplasia (81.14, 24.33, 14.17 respectively). Soluble CD44 was the most elevated in patients with non-dysplastic lesions (2.49). The HMGB1, KLK6 and VE-cad serum levels were increasing from non-dysplastic to low-grade dysplasia and followed by the decrease for high-grade dysplasia and invasive cancer, however the differences were not significant (p-values 0.897, 0.354, 0.1 respectively). Patients’ serum had the highest CD44 concentration in non-dysplastic and low-grade dysplasia with the following decrease through high-grade dysplasia and invasive cancer. GERD symptomatic patients had higher levels of KLK6 and CD44 than other patients (p-value 0.06 and 0.084 respectively). There were no significant differences of biomarkers levels related to patients’ gender (p-value from 0.243 to 1) or smoking status (p-value from 0.22 to 0.706). CONCLUSIONS: VE-cad, HMGB1, CD44 and KLK6 did not prove to be reliable biomarkers implicating malignant potential within vocal fold hypertrophic intraepithelial lesions. PeerJ Inc. 2022-04-19 /pmc/articles/PMC9029362/ /pubmed/35462765 http://dx.doi.org/10.7717/peerj.13104 Text en © 2022 Żurek et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
spellingShingle Hematology
Żurek, Michał
Rzepakowska, Anna
Kotuła, Iwona
Demkow, Urszula
Niemczyk, Kazimierz
Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title_full Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title_fullStr Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title_full_unstemmed Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title_short Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
title_sort serum expression of vascular endothelial-cadherin, cd44, human high mobility group b1, kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer
topic Hematology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029362/
https://www.ncbi.nlm.nih.gov/pubmed/35462765
http://dx.doi.org/10.7717/peerj.13104
work_keys_str_mv AT zurekmichał serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer
AT rzepakowskaanna serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer
AT kotułaiwona serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer
AT demkowurszula serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer
AT niemczykkazimierz serumexpressionofvascularendothelialcadherincd44humanhighmobilitygroupb1kallikrein6proteinsindifferentstagesoflaryngealintraepitheliallesionsandearlyglottiscancer